Vimarsana
Biggest News Aggregation in the World

Page 2 - Mayo Score News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mayo Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mayo Score Today - Breaking & Trending Today

AbbVie Submits Application to FDA for Risankizumab in Ulcerative Colitis - Vimarsana News

AbbVie Submits Application to FDA for Risankizumab in Ulcerative Colitis

AbbVie submitted regulatory applications to the FDA and EMA for rizankizumab 1200 mg intravenous induction dose and 180 mg and 360 mg subcutaneous maintenance dose following successful Phase 3 trials INSPIRE and COMMAND.

AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis - Vimarsana News

AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis

Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission and key secondary endpoints as an induction and maintenance...

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase ... - Vimarsana News

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase ...

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase ...

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase 2b Maintenance Trial in Ulcerative Colitis - Vimarsana News

Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase 2b Maintenance Trial in Ulcerative Colitis

The analysis demonstrates clinical remission in 52.5% (n=114) of 217 moderate to severe ulcerative colitis (UC) patients (intent-to-treat population, ITT) after two years (96 weeks) of once-daily oral

EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis - Vimarsana News

EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis

EQS-News: ABIVAX / Key word(s): Study results Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance tri...